Cascade Prodrug Inc. Appoints Industry Veterans Manuel (Manny) Litchman and Andres Gutierrez to Board of DirectorsEUGENE, Ore., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cascade Prodrug, Inc. (“Cascade”), a biotechnology company focused on advancing novel Hypoxia Activated Therapies in oncology, today announced the appointment of Manuel (Manny) Litchman, M.D. and Andres Gutierrez M.D., Ph.D. to its Board of Directors.
Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual MeetingEUGENE, Ore., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cascade Prodrug Inc. (Cascade), a private preclinical-stage biotechnology company focused on developing novel small molecule therapeutics targeting hypoxia, today announced a poster presentation highlighting preclinical data for it's lead candidate CPD100Li at the SITC 2023 Annual Meeting, being held November 3-5 in San Diego, CA.
